GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sunshine Biopharma Inc (NAS:SBFM) » Definitions » 5-Year Yield-on-Cost %

Sunshine Biopharma (Sunshine Biopharma) 5-Year Yield-on-Cost % : 0.00 (As of Jun. 07, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Sunshine Biopharma 5-Year Yield-on-Cost %?

Sunshine Biopharma's yield on cost for the quarter that ended in Mar. 2024 was 0.00.


The historical rank and industry rank for Sunshine Biopharma's 5-Year Yield-on-Cost % or its related term are showing as below:



SBFM's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.245
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Sunshine Biopharma's 5-Year Yield-on-Cost %

For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunshine Biopharma's 5-Year Yield-on-Cost % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Sunshine Biopharma's 5-Year Yield-on-Cost % falls into.



Sunshine Biopharma 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Sunshine Biopharma is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Sunshine Biopharma  (NAS:SBFM) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Sunshine Biopharma 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Sunshine Biopharma's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunshine Biopharma (Sunshine Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, QC, CAN, H9R 0A5
Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5).
Executives
Camille Sebaaly director, officer: CFO and Secretary 14464 GOUIN W., #B, MONTREAL A8 H9H 1B1
Malek Chamoun 10 percent owner 1730 RUE SAINT-PATRICK UNIT 601, MONTREAL Z4 H3K0B2
David Natan director 11190 BISCAYNE BLVD, MIAMI FL 33181
Andrew Mark Keller director 10 ISLAND DRIVE, NORWALK CT 06855
Andrew I Telsey director 6198 SOUTH MOLINE COURT, ENGLEWOOD CO 80111
James Daniel Kish director 6456 S QUEBEC ST., SUITE 550, CENTENNIAL CO 80111
Rabi Kiderchah director 924 PIERRE-DANSEREAU AVE, APT 206, TERREBONNE A8 J6Y 0N3
Advanomics Corp 10 percent owner 579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4
Steve N. Slilaty director, 10 percent owner, officer: CEO and President 579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4
Abderrazzak Merzouki director, officer: Chief Operating Officer 731 PLACE DE L'EEAU VIVE, LAVAL A8 H7Y 2E1
Turi Michele Di director, officer: Chief Operating Officer 3100 BOUL. DES GOUVERNEURS, LAVAL A8 H7E 5J3